AdAlta is a biotechnology company that is focused on developing its lead i-body drug candidate, AD-114, for the treatment of idiopathic pulmonary (lung) fibrosis (IPF) and other fibrotic diseases, for which current therapies have limited efficacy where there is a high-unmet medical need. The lead drug candidate AD-114 has shown both anti-fibrotic activity as well as anti-inflammatory activity in pre-clinical studies, which are important for the treatment and prevention of IPF.

It is anticipated that 1AD will list on the ASX during August 2016.